TY - JOUR
T1 - Transforming growth factor beta 1 (TGF-β1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs
AU - Kawamoto, Koichi
AU - Pahuja, Anil
AU - Hering, Bernhard J.
AU - Bansal-Pakala, Pratima
N1 - Funding Information:
This work was supported by the Richard M. Schulze Family Foundation.
PY - 2010/5
Y1 - 2010/5
N2 - Background: The major obstacle faced by patients with type 1 diabetes who undergo islet transplantation is a gradual decline in insulin independence. This decline may reflect alloimmune rejection, autoimmune recurrence and toxicity of drugs such as rapamycin to islet β cells. Thus, there is a pressing need to refine immunosuppressive protocols in order to reduce toxicity to islet grafts and yet prevent rejection. Recent studies demonstrated that TGF-β1 is a critical cytokine for the regulation of immune responses. In naive T cells, TGF-β1 induces FoxP3+ regulatory T cells and thus could promote transplant tolerance. In this study, in vitro experiments were performed to determine whether TGF-β1 could synergize with low-dose rapamycin and inhibit T cell activation and production of inflammatory cytokines, as well as enhance FoxP3 expression for potential application in islet transplantation. Methods: Human peripheral blood mononuclear cells were stimulated with either anti-CD3/CD28 or anti-CD3 during TGF-β1 and rapamycin treatment. Results: TGF-β1 inhibited T cell proliferation induced with anti-CD3 stimulation, but not with anti-CD3/CD28 stimulation. The combination of these reagents produced a synergistic inhibition of T cell proliferation induced with both anti-CD3/CD28 and anti-CD3 stimulations. Moreover, TGF-β1 and rapamycin significantly suppressed cytokine production and induced regulatory T cells by upregulating FoxP3 expression. Conclusions: These results suggest that the combination of TGF-β1 and low-dose rapamycin can potently inhibit T cell responses in vivo and would be beneficial in supporting islet graft survival by limiting toxicity and preventing immune rejection.
AB - Background: The major obstacle faced by patients with type 1 diabetes who undergo islet transplantation is a gradual decline in insulin independence. This decline may reflect alloimmune rejection, autoimmune recurrence and toxicity of drugs such as rapamycin to islet β cells. Thus, there is a pressing need to refine immunosuppressive protocols in order to reduce toxicity to islet grafts and yet prevent rejection. Recent studies demonstrated that TGF-β1 is a critical cytokine for the regulation of immune responses. In naive T cells, TGF-β1 induces FoxP3+ regulatory T cells and thus could promote transplant tolerance. In this study, in vitro experiments were performed to determine whether TGF-β1 could synergize with low-dose rapamycin and inhibit T cell activation and production of inflammatory cytokines, as well as enhance FoxP3 expression for potential application in islet transplantation. Methods: Human peripheral blood mononuclear cells were stimulated with either anti-CD3/CD28 or anti-CD3 during TGF-β1 and rapamycin treatment. Results: TGF-β1 inhibited T cell proliferation induced with anti-CD3 stimulation, but not with anti-CD3/CD28 stimulation. The combination of these reagents produced a synergistic inhibition of T cell proliferation induced with both anti-CD3/CD28 and anti-CD3 stimulations. Moreover, TGF-β1 and rapamycin significantly suppressed cytokine production and induced regulatory T cells by upregulating FoxP3 expression. Conclusions: These results suggest that the combination of TGF-β1 and low-dose rapamycin can potently inhibit T cell responses in vivo and would be beneficial in supporting islet graft survival by limiting toxicity and preventing immune rejection.
KW - Anti-CD3
KW - Human T cells
KW - Islet transplantation
KW - Rapamycin (sirolimus)
KW - TGF-β1
UR - http://www.scopus.com/inward/record.url?scp=77953807734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953807734&partnerID=8YFLogxK
U2 - 10.1016/j.trim.2010.03.004
DO - 10.1016/j.trim.2010.03.004
M3 - Article
C2 - 20307666
AN - SCOPUS:77953807734
VL - 23
SP - 28
EP - 33
JO - Transplant Immunology
JF - Transplant Immunology
SN - 0966-3274
IS - 1-2
ER -